Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE)

Peer Review reports

Original Submission
1 Jul 2021	Submitted	Original manuscript
31 Jul 2021	Reviewed	Reviewer Report - Han Zhu
10 Aug 2021	Reviewed	Reviewer Report - Pradeep Virdee
20 Aug 2021	Reviewed	Reviewer Report - Cristina Martín-Arriscado
10 Sep 2021	Author responded	Author comments - Consuelo Nohpal de la Rosa
Resubmission - Version 2
10 Sep 2021	Submitted	Manuscript version 2
19 Sep 2021	Reviewed	Reviewer Report - Han Zhu
21 Sep 2021	Reviewed	Reviewer Report - Cristina Martín-Arriscado
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
29 Sep 2021	Editorially accepted
5 Jan 2022	Article published	10.1186/s13063-021-05669-9

Back to article page